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Defining the full complement of substrates for each ubiquitin ligase remains an important challenge. Improvements in mass
spectrometry instrumentation and computation and in protein biochemistry methods have resulted in several new methods for
ubiquitin ligase substrate identification. Here we used the parallel adapter capture (PAC) proteomics approach to study
TrCP2/FBXW11, a substrate adaptor for the SKP1–CUL1–F-box (SCF) E3 ubiquitin ligase complex. The processivity of the
ubiquitylation reaction necessitates transient physical interactions between FBXW11 and its substrates, thus making biochemi-
cal purification of FBXW11-bound substrates difficult. Using the PAC-based approach, we inhibited the proteasome to “trap”
ubiquitylated substrates on the SCFFBXW11 E3 complex. Comparative mass spectrometry analysis of immunopurified FBXW11
protein complexes before and after proteasome inhibition revealed 21 known and 23 putatively novel substrates. In focused
studies, we found that SCFFBXW11 bound, polyubiquitylated, and destabilized RAPGEF2, a guanine nucleotide exchange factor
that activates the small GTPase RAP1. High RAPGEF2 protein levels promoted cell-cell fusion and, consequently, multinucle-
ation. Surprisingly, this occurred independently of the guanine nucleotide exchange factor (GEF) catalytic activity and of the
presence of RAP1. Our data establish new functions for RAPGEF2 that may contribute to aneuploidy in cancer. More broadly,
this report supports the continued use of substrate trapping proteomics to comprehensively define targets for E3 ubiquitin li-
gases. All proteomic data are available via ProteomeXchange with identifier PXD001062.
Ubiquitylation is a posttranslational modification that controlsprotein-protein interactions, protein subcellular localization,
protein-mediated catalysis, and, most famously, protein stability.
The enzymology of protein ubiquitylation is now fairly well un-
derstood and has been well summarized in several recent reviews
(1–3). The last and arguably most important step in the ubiquity-
lation reaction is carried out by an E3 ubiquitin ligase. These pro-
teins select substrates for ubiquitylation, physically bridge and ori-
ent the substrate with ubiquitin, and in some cases, directly
catalyze ubiquitin transfer. E3 ligases also provide the cell with a
means to dynamically regulate substrate ubiquitylation; the inter-
action of a substrate protein with its cognate E3 ligase is often
influenced by peripheral signals, such as phosphorylation (4). In
total, more than 600 distinct E3 ubiquitin ligases have been iden-
tified within the human genome (5), the vast majority of which
remain unstudied. Current estimates suggest that these ligases tar-
get more than 9,000 distinct human proteins for ubiquitylation, or
roughly 40% of the protein-coding human genome (6, 7). For
most of these proteins, the physiological importance of ubiquitin
conjugation is not known. Likewise, paired relationships between
specific E3 ligases and substrates are for the most part not known.
Until recently, substrate identification for specific ubiquitin
ligase complexes has been a major hurdle for the ubiquitylation
community (reviewed in reference 8). Focused biochemical and
genetic studies have succeeded in revealing substrates but have
done so for only a small number of well-studied ligases. The dif-
ficulty lies in the transient nature of the E3-substrate interaction
and in the often low cellular abundance of substrate protein. Con-
sequently, substrates are often missed in biochemical analyses of
immunopurified E3 complexes. New experimental approaches
are beginning to overcome this problem (8–10). Short-term treat-
ment of cells with inhibitors of the ubiquitylation cycle results in
substrate stabilization and, importantly, accumulation of the sub-
strate-E3 complex. This has previously been achieved with small
molecules that block the proteasome or cullin neddylation (11–
13). Consequently, protein mass spectrometry (MS) analysis of
the immunopurified ligase complex before and after proteasome
or NEDD8 inhibition reveals the identity and quantity of trapped
substrates; this approach was recently termed parallel adaptor
capture proteomics (PAC) (13). Similarly, purification of mutant
E3 adapter proteins, where the engineered mutation blocks sub-
strate turnover but not substrate binding, revealed known and
novel substrates (14). Taking an in vitro approach, Michele Pa-
gano and colleagues have used immunoprecipitated E3 protein
complexes and exogenous epitope-tagged ubiquitin to identify
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numerous novel ubiquitylated substrates (10, 15, 16). Two addi-
tional discovery platforms provide powerful complementation of
these substrate identification approaches. First, ubiquitin rem-
nant proteomic analyses performed via immunopurification of
Lys-ε-Gly-Gly (diGly) modified peptides and mass spectrometry
revealed global proteome ubiquitylation (17). Second, the Global
Protein Stability (GPS) platform quantifies dynamic changes in
protein stability following genetic perturbation of specific ubiqui-
tylation machinery (18, 19). Proteins identified through either
diGLY or GPS analysis should be enriched within PAC-derived
interaction networks.
Here, we have taken a PAC-based approach to identify sub-
strates for the TrCP2/FBXW11 E3 ubiquitin ligase. FBXW11 and
its related paralogue TrCP1/BTRC are F-box domain-contain-
ing proteins that serve as substrate adaptor proteins within SKP1-
and CUL1-containing E3 ubiquitin ligase complexes; together,
these proteins constitute SCFFBXW11 or SCFBTRC. FBXW11 and
BTRC are among the best-studied E3 proteins, with at least 30
identified substrates and well-described roles in controlling cell
cycle and signal transduction (20). Using substrate trapping pro-
teomic analysis of FBXW11, we identified 21 previously reported
substrates and 23 novel candidate substrates. These data and re-
cent PAC-based proteomic studies suggest that, despite more than
a decade of research, the full complement of FBXW11 and BTRC
substrates is not yet known.
This report focuses on a new FBXW11 substrate, RAPGEF2
(also called PDZ-GEF1, RA-GEF1, nRAPGEF, and CNrasGEF).
RAPGEF2 is a guanine nucleotide exchange factor (GEF) for
the RAP1 and RAP2 (RAP1/2) small GTPases (21). In addition
to a C-terminal RAPGEF catalytic CDC25 homology domain,
RAPGEF2 contains amino-terminal cNMP, PDZ, and RA do-
mains. RAP protein activity is governed by nucleotide binding;
GEFs catalyze the exchange of GDP for GTP, thus promoting for-
mation of active RAP. Conversely, GTPase activating proteins
(GAP) trigger the hydrolysis of GTP to GDP and formation of
inactive RAP-GTP (22). Genetic studies in Caenorhabditis elegans,
Drosophila, and mice describe vital functions for RAPGEF2 in
controlling RAP1-dependent modulation of the actin cytoskele-
ton, leading to decreased cell adhesion, cell polarity, cell-cell con-
tacts, and cell migration (23–25). Mice deficient for RAPGEF2
display multiple developmental defects, including reduced vascu-
lar barrier formation (26). A role for RAPGEF2 in cancer, albeit
complex and tissue specific, has also emerged. First, a murine
piggyBac insertional mutagenesis screen identified RAPGEF2 and
its associated protein MAGI1 as “driver” genes in melanoma (27).
Second, RAPGEF2 controls the migratory capacity of multiple cell
types. For example, its expression inhibited breast cancer cell mi-
gration in vitro and suppressed cell invasion/metastasis in a ze-
brafish xenograft model (28). Third, RAPGEF2 activation of
RAP1 in turn activated B-Raf and the extracellular signal-regu-
lated kinase (ERK) mitogen-activated protein kinase cascade in
multiple cell types, including neurons and endocrine cells (29).
Together, these and many other reports describe evolutionarily
conserved and fundamental roles for RAPGEF2 in development
and disease.
Using PAC-based proteomic analysis, we discovered known
and novel substrates for FBXW11, including RAPGEF2, TBC1D4,
STK3, RASSF3, and AEBP2. Our focused experiments confirm
and extend recent findings that RAPGEF2 is a physiologically im-
portant substrate for FBXW11 (28). We report a GEF activity- and
RAP1-independent function for RAPGEF2 in promoting cellular
multinucleation which, remarkably, occurs through cell-cell fu-
sion events.
MATERIALS AND METHODS
Expression vectors and site-directed mutagenesis. The FLAG-RAPGEF2
and YFP-RAPGEF2 expression vectors were generous gifts from Lawrence
Quillam (Indiana University) and Johannes L. Bos (University Medical
Centre Utrecht, Netherlands), respectively. The hemagglutinin (HA)-
ubiquitin expression plasmid was a gift from Yue Xiong, University
of North Carolina at Chapel Hill. The three truncation mutations
(RAPGEF2-1, -2, and -3) and a point mutation (RAPGEF2-2SA)
were generated by PCR-based mutagenesis using Pfu DNA polymerase.
The sense primer sequence for the point mutation is as follows: 5=-TGA
TGC TGC TGA CGC TGG C CG TGG GGC CTG GAC GTC ATG CT-3=.
A GEF-dead mutant of RAPGEF was generated by sequential PCRs to
generate YFP-RAPGEF2 (K875A/F879A/N884A; 3M). The double point
mutation (F879A/N884A) was first created using the following sense
primer: 5=-AAA G GA TCT CAC CGC CCT TCA CGA AGG AGC TGA
CTC AAA AGT AG-3=. The triple point mutation (K875A/F879A/
N884A) was then generated using the F879A/N884A construct as a tem-
plate and the following sense primer: 5=-CTA TTC CCA GTT ATC AAA
GCG GAT CTC ACC GCC CTT CAC-3=. The presence of point muta-
tions was verified by DNA sequencing. Generation and characterization
of the SBPHA-BTRC, SBPHA-FBXW11, SBPHA-CTNNB1SA, FLAG-
BTRC, and FLAG-FBXW11 expression vectors were previously reported
(30).
Cell culture, transfections, and siRNAs. HEK293 cells were main-
tained in Dulbecco’s modification of Eagle’s medium (DMEM) supple-
mented with 10% fetal bovine serum (FBS; HyClone) in a 37°C humidi-
fied incubator with 5% CO2. Transfection of expression plasmids was
done with Lipofectamine 2000 (Invitrogen) or Transit (Myrus), while
transfection of small interfering RNA (siRNA) was done with Lipo-
fectamine RNAiMAX, as directed by the manufacturer’s instructions. All
siRNAs were used at a final concentration of 20 nM and for 72 h unless
otherwise stated. siRNA sequences were as follows: for BTRC/FBXW11
(this siRNA targets identical sequences in BTRC and FBXW11), GUG
GAA UUU GUG GAA CAU C deoxyribosylthymine (dT) dT; for
RAPGEF2-A, CAG UGG AAC CUU AUC AUC CAG UAA U; for
RAPGEF2 B, GGG UGG AAA GGA UGU UUC CAU UGA A;
for NEDD4-A, GGA UAA ACU UCA GAU GGC AAU UGA A; and for
NEDD4-B, GGA UCA GAA AUA GUU GUC ACC AAU A. Nontargeting
control siRNA was obtained from Dharmacon and Invitrogen. Genera-
tion of monoclonal cells stably expressing RAPGEF2 was achieved by
Lipofectamine transfection of HEK293 cells with YFP-RAPGEF2 plasmid,
followed by fluorescence-activated cell sorter analysis (FACS) of yellow
fluorescent protein (YFP)-positive single cells on a 96-well plate and ex-
pansion of monoclonal populations.
Western blotting and immunoprecipitation. In all biochemical ex-
periments, cell lysates were prepared in a buffer containing 50 mM Tris-
HCl (pH 7.5), 150 mM NaCl, 1% NP-40, 10 mM NaF, 5 mM EDTA, and
protease and phosphatase inhibitor cocktail (Roche). For immunopre-
cipitation, equal amounts of precleared cell lysates were incubated with 1
g of the indicated antibody or control IgG overnight. Protein A/G-Sep-
harose beads (GE Healthcare) were added to each of the samples, and the
reaction mixtures were further incubated for 2 to 3 h and washed three
times. Bound proteins were eluted from the beads with SDS-PAGE sample
buffer, and Western blotting was performed with the following antibod-
ies: anti-FLAG M2 monoclonal (Sigma-Aldrich Corporation), anti-HA
monoclonal (MMS-101P; Covance), anti-green fluorescent protein (anti-
GFP) polyclonal (ab290; Abcam), anti-RAPGEF2 polyclonal (A301-
966A; Bethyl Laboratories), anti-Rap1 polyclonal (sc-65; Santa Cruz
Biotechnology), anti-BTRC (D13F10; Cell Signaling Technology), anti-
BTRC/FBXW11 (37-3400; Invitrogen), anti-CTNNB1 polyclonal (9562;
Cell Signaling Technology), anti-NEDD4 (3606; Cell Signaling Technol-
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ogy), USP47 (A301-048A; Bethyl Laboratories), DOCK1 (sc-13163; Santa
Cruz Biotechnology), NUDC (10681-1-AP; ProteinTech Group), DAP3
(H00007818-A01; Abnova), STK3 and STK4 (STK3/4) (A300-466A;
Bethyl Laboratories), TBC1D4 (ab24469; Abcam), SKP1 (2156; Cell
Signaling Technology), anti--tubulin monoclonal (T7816; Sigma-
Aldrich), and antiactin polyclonal (A2066; Sigma-Aldrich) (recog-
nizes , , and ) antibodies.
Protein identification. FLAG immunoprecipitation, trypsinization,
and mass spectrometry were performed exactly as previously reported
(31). SBP_CBP-based tandem affinity purification and mass spectrome-
try (TAPMS) were performed as previously described (32). The peptide
mixture was analyzed in positive mode using a nanoAquity ultraperfor-
mance liquid chromatography (UPLC)-coupled LTQ Orbitrap Elite mass
spectrometer (Thermo Scientific). Chromatographic separation used a
2-cm-long trapping column and a self-packed 25-cm-long analytical col-
umn (75 m inner diameter [ID]) and Michrom Magic C18 beads of
5.0-m particle diameter and 100-Å pore diameter. The HPLC flow rate
was set to 350 nl/min over a gradient of 1% buffer B (0.1% formic acid–
acetonitrile) to 35% buffer B in 200 min. The full mass scan (300 to 2,000
m/z) was acquired at a resolution of 60,000 with a maximum injection
time of 500 ms, and tandem MS (MS/MS) was performed in a data-
dependent manner for the top 15 ions exhibiting the greatest intensity in
the linear ion trap by collision-induced dissociation. All raw spectral data
were converted to mzXML format before a search of the resultant spectra
with Sorcerer-SEQUEST (build 4.3.0; Sage-N Research) and the Trans-
Proteomic Pipeline (TPP v4.6.2) was performed. Data were searched
against the human UniProtKB/Swiss-Prot sequence database (Release
2013_07) supplemented with common contaminants, such as porcine
(Swiss-Prot P00761) and bovine (P00760) trypsin, and further concate-
nated with the reversed copy of each sequence as a decoy (40,526 total
sequences). Search parameters used were a precursor mass between 400 and
4,500 atomic mass units (amu), up to two missed cleavages, a precursor-ion
tolerance of three amu, accurate mass binning within PeptideProphet (33),
semitryptic digestion, a static carbamidomethyl cysteine modification,
and variable methionine oxidation. False-discovery rates (FDRs) were
determined by ProteinProphet (33), and minimum protein probability
cutoffs resulting in a 1% FDR were selected individually for each experi-
ment. The mass spectrometry proteomics data have been deposited into
the ProteomeXchange Consortium (34) via the PRIDE partner repository
with the data set identifier PXD001062.
Bioinformatics. PeptideProphet/ProteinProphet results for each
APMS experiment were stored in a local Prohits database (35). Candidate
protein interactions from APMS experiments were filtered using the
CompPASS algorithm. FLAG and TAPMS background data sets required
for CompPASS were obtained from previous experiments performed by
our laboratory. Experiments performed with MG132 or dimethyl sulfox-
ide (DMSO) treatment were scored separately from each other. Network
visualization was achieved using Cytoscape v3.1.0 (36). Known protein-
protein interactions were extracted from the 04/2014 build of BioGRID.
Multiple-sequence alignment for analysis of a short amino acid motif in
substrate proteins referred to as a degron was performed using GLAM2
and GLAM2SCAN (37).
In vivo ubiquitylation assays. HEK293 cells were transfected with
plasmids expressing FLAG-RAPGEF2 and HA-ubiquitin for 24 h and
treated with DMSO or 10 M MG132 for 6 h. For BTRC/FBXW11 knock-
down, control or BTRC/FBXW11 siRNAs were transfected 24 h prior to
plasmid transfection. The cells were lysed with SDS lysis buffer (50 mM
Tris-HCl at pH 8.0, 100 mM NaCl, 2% Triton X-100, 1% SDS) and boiled
for 10 min. Lysates were then diluted 10 with NP-40 buffer (50 mM
Tris-HCl at pH 7.5, 150 mM NaCl, 0.5% NaCl, 50 mM NaF). The diluted
lysates were applied to immunoprecipitation with anti-M2 FLAG affinity
gel (Sigma). The immunoprecipitated proteins were analyzed by Western
blotting with anti-HA antibody for the detection of ubiquitin-conjugated
RAPGEF2.
RAP1 activity assay. RAP1 activity was examined by a pulldown
method using a glutathione S-transferase (GST) fusion of an isolated
RAP-GTP binding domain (RBD) of RalGDS (GST-RalGDS-RBD) as de-
scribed previously (38). Briefly, HEK293 cells plated in a 60-mm-diameter
culture dish were transfected with 3 g of empty plasmid (Mock),
RAPGEF2 (wild type [WT]), or RAPGEF2 (K875A/F879A/N884A; 3M)
for 24 to 36 h, lysed in 300 l of ice-cold cell lysis buffer (50 mM Tris-HCl
[pH 7.5], 150 mM NaCl, 1% NP-40, 5 mM MgCl2, 10% glycerol, protease
inhibitor cocktail), and clarified by centrifugation at 14,000 rpm for 10
min at 4°C. A 5% aliquot was removed for determination of the total
quantities of the RAP1 being analyzed. Cleared lysates were then incubated
with 30 g of GST-RalGDS (RBD) protein precoupled to glutathione-
Sepharose 4B beads for 1 h at 4°C and washed three times with the lysis
buffer. The samples were analyzed by immunoblotting using anti-RAP1
antibody to detect bound activated RAP1-GTP. Whole-cell lysates were
also analyzed for the presence of expressed RAP1.
Immunofluorescence. For cell staining, HEK293 cells were plated on
fibronectin-coated coverslips and allowed to attach and spread at 37°C in
complete growth medium. Cells were transfected with the plasmids or
siRNAs of interest and fixed 24 to 72 h after transfection as indicated.
Fixation was performed with 4% paraformaldehyde (PFA; Electron Mi-
croscopy Sciences)– cytoskeletal buffer {5 mM PIPES [piperazine-N,N=-
bis(2-ethanesulfonic acid)] (pH 6), 137 mM NaCl, 5 mM KCl, 1.1 mM
sodium phosphate buffer, 0.4 mM KH2PO4, 0.4 mM MgCl2, 0.4 mM
NaHCO3, 2 mM EGTA, 50 mM glucose} for 15 min and permeabilization
with 0.1% Triton X-100 –phosphate-buffered saline (PBS) for 5 min. Af-
ter being blocked in 1% bovine serum albumin–PBS for 1 h, cells were
incubated with primary antibodies at 4°C overnight, followed by incuba-
tion with appropriate secondary antibodies, Rhodamine Red X (RRX)-
conjugated donkey anti-mouse immunoglobulin G (IgG), fluorescein iso-
thiocyanate-conjugated donkey anti-mouse IgG, and Cy5-conjugated
donkey anti-goat antibody (Jackson ImmunoResearch Laboratories), at
room temperature for 2 h. The following antibodies were used: monoclo-
nal anti--tubulin (clone DM1A [T9026]; Sigma-Aldrich Corporation),
monoclonal anti-CTNNB1 (BD Transduction Laboratories), and goat
IgG anti-lamin B (Santa Cruz). Coverslips were mounted to slides with
ProLong Gold antifade reagent containing DAPI (4=,6-diamidino-2-
phenylindole; Invitrogen) for nuclear staining. Staining was analyzed
with an Olympus BX61 upright wide-field microscope (Olympus Corpo-
ration of the Americas) equipped with 40/1.3-numerical aperture (NA)
oil UPlanFLN and 60/1.42-NA oil PlanApo objective lenses and a
Hamamatsu Orca RC camera (Hamamatsu Photonics Ltd.). For analysis
of mitotic spindles, samples were processed as described above and ana-
lyzed with a Zeiss CLSM 700 confocal laser scanning microscope
equipped with a 63/1.4-NA PlanApo oil objective lens. Image process-
ing was performed with ImageJ and Adobe Photoshop CS software.
Flow cytometry. HEK293 cells were transiently transfected with WT-
RAPGEF2 or dead-RAPGEF2 or mock transfected, harvested after 48 h by
using trypsin-EDTA, and resuspended in 10% FBS–DMEM. Cells (1.5 
106) were fixed in 70% ethanol, treated with RNase A, and stained with 20
g/ml propidium iodide for analysis of DNA content using a CyAn ADP
analyzer (Beckman Coulter). Sequential gating was done to exclude cell
debris, aggregates, and nontransfected cells. Percentages of cells in the
G0/G1, S, and G2/M stages of the cell cycle were determined by using
ModiFit (Verity Software House, Topsham, ME). A total of 30,000 events
were acquired for each of three replicate biological experiments.
Live cell imaging. HEK293 cells were transfected with YFP-WT-
RAPGEF2 or cotransfected with YFP-WT-RAPGEF2 and cherry-nuclear
localization signal (cherry-NLS) and imaged the next day. Time-lapse
phase-contrast and fluorescence images were acquired every 6 min for 10
h with an Olympus IX70 inverted fluorescence microscope enclosed
within an environmental chamber controlled for temperature, relative
humidity, and CO2 and equipped with 10/0.30-NA Ph1 UPlanFL and
20/0.40-NA Ph1 LCPlanFL objective lenses and a Hamamatsu Orca
C4742-95 charge-coupled device camera. Data acquisition was carried out
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with Volocity (version 5.5.1; PerkinElmer), and image processing was
performed with ImageJ and Adobe Photoshop CS software.
RESULTS
Identification of FBXW11 substrates by APMS. The FBXW11
and BTRC protein-protein interaction networks were defined in
HEK293T human embryonic kidney cells by tandem affinity pu-
rification and mass spectrometry (TAPMS). HEK293T cells were
engineered to stably express FBXW11 or BTRC amino terminally
tagged with streptavidin binding peptide (SBP), calmodulin bind-
ing peptide (CBP), and hemagglutinin (HA) epitope. The result-
ing cell lines were solubilized in duplicate biological experiments
using 0.1% NP-40 or 1% Triton X-100 before TAPMS analysis.
After removing false-positive interactions with the CompPASS
algorithm (39), FBXW11 and BTRC were found to interact with
96 and 26 proteins, respectively (Fig. 1A). Twenty proteins co-
complexed with both FBXW11 and BTRC baits. Previously un-
studied interacting proteins included NUDC, OGT, DOCK1, and
ELMO2. As expected from their instability and transient interac-
tions with the E3 enzyme, many previously reported substrates,
including ATF4, NFKB1, PER1, and WEE1, were not identified.
Therefore, the purifications were repeated before and after a 4-h
treatment with MG132 proteasome inhibitor, in replicate biolog-
ical experiments. Label-free quantitation and ratiometric analysis
revealed associated proteins that increased in abundance within
the FBXW11 complex following proteasome inhibition (Fig. 1B).
Many previously reported substrates, including the aforemen-
tioned substrates and NFE2L2, DEPTOR, and CDC25A, were de-
tected only after MG132 treatment. In fact, the levels of 32 pro-
teins demonstrated a median 2-fold or greater increase following
MG132 treatment, compared to two proteins and the mitoribo-
some, whose levels decreased after treatment. Based on these ex-
periments, putative novel substrates included APC, MTSS1L,
TFAP4, RASSF3, MAST3, and AEBP2.
FBXW11 and BTRC bind a short amino acid motif in substrate
proteins referred to as a degron. Focused study of many known
substrates has defined the consensus degron to be DSGXXS. To
identify degron-containing proteins, including degron variants,
within the FBXW11 and BTRC interaction networks, we used the
GLAM2 algorithm and the sequence of known substrates to
probabilistically reveal position-specific preferences within the
degron (Fig. 1C). This revealed that 65 of 151 FBXW11 interacting
proteins contained a statistically defined degron sequence (shown
as orange nodes within Fig. 1). Importantly, these proteins dem-
onstrated a statistically significant increase in the response to
MG132 compared to degron-deficient FBXW11 interacting pro-
teins (two-tailed t test with unequal variance, P  0.034). We
validated several of the FBXW11 protein interactions, including
those whose interactions were stabilized by MG132 treatment.
Streptavidin affinity purification of SBPCBPHA-FBXW11 and
Western blot analysis confirmed associations with DOCK1,
NUDC, DAP3, and USP47. MG132-induced interactions with
STK3/STK4 and TBC1D4 were also confirmed (Fig. 1D). As
a control, we confirmed that SBPCBPHA-tagged-CTNNB1SA,
which does not bind FBXW11 or BTRC, did not cocomplex with
the analyzed proteins.
RAPGEF2 is an FBXW11 substrate. Among the FBXW11 in-
teracting proteins that contained a predicted degron and re-
sponded to MG132 treatment, we selected RAPGEF2 for fur-
ther validation and functional study. We first validated the
protein-protein interactions by immunoprecipitation-Western
blot analysis, RAPGEF2 PAC-based proteomics, and subcellular
colocalization studies. Western blot analysis of immunopurified
FLAG-tagged FBXW11 revealed an MG132-induced associa-
tion with endogenous RAPGEF2. Importantly, this short treat-
ment did not result in an increase in total cellular levels of
RAPGEF2 (Fig. 2A). Reciprocally, endogenous BTRC was de-
tected in protein complexes isolated by immunopurification of
ectopically expressed FLAG-RAPGEF2 following MG132 treat-
ment; antibodies which recognize endogenous FBXW11 are
not available (Fig. 2B). In agreement, we found that overex-
pressed RAPGEF2 was immunoprecipitated with both BTRC
and FBXW11 after MG132 treatment (Fig. 2C).
Next, we defined the RAPGEF2 protein interaction network by
FLAG-based immunoprecipitation and mass spectrometry
(IPMS) before and after a 2-h MG132 treatment (Fig. 2D). The
MAGI1 and MAGI3 proteins, which are known RAPGEF2 inter-
acting proteins, were detected irrespective of the presence or ab-
sence of MG132 treatment. Novel putative interacting proteins,
including TJP1 (ZO1/2), PTPN13, TNKS, and EPB41L5, were also
discovered. In agreement with the FBXW11 APMS profiling,
MG132 treatment resulted in a greater than 5-fold increase in the
FBXW11 level within the RAPGEF2 protein complex (Fig. 2E).
Finally, to complement the biochemistry, we determined the
subcellular distribution of RAPGEF2, BTRC, and FBXW11 in
HEK293 cells by epifluorescence microscopy (Fig. 2F). When ex-
pressed alone, YFP-RAPGEF2 exhibited a cytosolic distribution
with apparent enrichment on centrosomes, proximal to nuclei
(Fig. 2F, arrowhead). Indeed, immunofluorescence staining of
HEK293 transfected with YFP-RAPGEF2 using antibodies against
-tubulin confirmed localization of RAPGEF2 to centrosomes
(data not shown). FLAG-BTRC was mainly nuclear, while FLAG-
FBXW11 exhibited a predominantly cytosolic distribution (Fig.
2F). Interestingly, and consistent with physical association, coex-
pression of YFP-RAPGEF2 with either FLAG-BTRC or FLAG-
FBXW11 resulted in subcellular redistribution of the protein
complex (Fig. 2G). Coexpressed FLAG-BTRC and YFP-RAPGEF2
colocalized in numerous cytoplasmic puncta, while coexpressed
FLAG-FBXW11 and YFP-RAPGEF2 colocalized in large cytoplas-
mic aggregates and, to a lesser extent, at the plasma membrane
(Fig. 2G, arrowhead and arrow, respectively). Confocal images of
HEK293 cells coexpressing FLAG-FBXW11 and YFP-RAPGEF2
further confirmed colocalization of these proteins and localized
the large aggregate to perinuclear space (Fig. 2H). Together, the
PAC analysis, focused biochemistry, and cell localization studies
confirm RAPGEF2 to be a MG132-induced FBXW11 and BTRC
interacting protein.
FBXW11 regulates RAPGEF2 protein stability. We next
tested whether FBXW11 and BTRC regulate RAPGEF2 protein
stability. First, RAPGEF2 protein levels increased following treat-
ment with MG132 proteasome inhibitor, implying that RAPGEF2
protein is regulated by proteasome-mediated degradation (Fig.
3A). Second, ectopic FBXW11 expression resulted in decreased
steady-state levels of coexpressed RAPGEF2 (Fig. 3B). Conversely,
concurrent siRNA-mediated silencing of both FBXW11 and
BTRC strongly increased the level of RAPGEF2 protein expres-
sion. This increase was detected by Western blotting and fluores-
cence microscopy (Fig. 3C and D, respectively). The NEDD4
ubiquitin ligase was previously reported to negatively regulate
RAPGEF2 protein stability (40). Compared to FBXW11/BTRC
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FIG 1 Substrate trapping proteomic analysis of FBXW11. (A) Annotated protein-protein interaction network for FBXW11 and BTRC in HEK293T cells.
High-confidence interactions are shown and were defined by the CompPASS scoring algorithm. Previously reported interactions that did not pass the
CompPASS threshold are noted with a dashed edge. Protein interactions were defined for FBXW11 in the absence and presence of MG132 (10 M, 2 h).
Complete unfiltered data are provided in Table S1 in the supplemental material. DB, database. (B) Spectral count ratios of FBXW11 interacting proteins after
treatment with MG132 or DMSO followed by either FLAG-FBXW11 or TAP-FBXW11 APMS. Box plots are representative of the results of four pairs of replicate
biological experiments. (C) Multiple-sequence alignment of published BTRC and FBXW11 substrate degrons. (D) HEK293T cells stably expressing SBPHA-
CTNNB1SA or SBPHA-FBXW11 were treated with 10 M MG132 for 2 h before lysis and streptavidin affinity purification (Strept. AP). Associated endogenous
proteins were detected by immunoblot analysis.




























































































































FIG 2 Proteasome inhibition increases the abundance of RAPGEF2 within FBXW11 and BTRC protein complexes. (A and B) Western blot analysis of
FLAG-FBXW11 (A) or FLAG-RAPGEF2 (B) immunopurified protein complexes before and after a 2-h MG132 treatment. TUBB, -tubulin. (C) HEK293 cells
were cotransfected with plasmids expressing FLAG-RAPGEF2 and HA-BTRC or HA-FBXW11, followed by treatment with DMSO or MG132 for 2 h. Cell lysates
or anti-HA immunoprecipitates were subjected to immunoblot analysis with the indicated antibodies. (D) HEK293T cells expressing FLAG-RAPGEF2 were
treated with MG132 for 2 h before lysis, FLAG immunoprecipitation, and mass spectrometry analysis. High-confidence protein interactions are shown, and data
indicate the dependency on MG132 treatment. (E) Spectral count ratios of RAPGEF2 interacting proteins (MG132/DMSO). (F) HEK293 cells transfected with
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silencing, siRNA-mediated suppression of NEDD4 did not affect
RAPGEF2 protein levels (Fig. 3C). Third, the half-live of endoge-
nous RAPGEF2 was increased in cells depleted of FBXW11/BTRC
relative to control siRNA transfected cells (Fig. 3E). Fourth,
FBXW11/BTRC control over RAPGEF2 protein levels was ob-
served in H2228 lung adenocarcinoma cells (Fig. 3F). In addition
to RAPGEF2, we also observed an increase in TBC1D4 and SUN2
levels following depletion of FBXW11/BTRC in both HEK293 and
H2228 cell lines, which supports the spectral ratios detected by
PAC-based analysis (Fig. 1B). Finally, we used small hairpin RNA
(shRNA) vectors to stably cosuppress FBXW11 and BTRC in
HEK293T cells. These cells express increased levels of RAPGEF2
and concordantly increased levels of GTP-bound RAP1, a RAPGEF2
substrate (Fig. 3G). Together, these data establish that FBXW11/
BTRC negatively regulates RAPGEF2 protein stability and ac-
tivity.
FBXW11 ubiquitinates RAPGEF2. To test whether FBXW11
or BTRC ubiquitinates RAPGEF2, we performed immunoprecipi-
tation and Western blot analyses under denaturing conditions.
siRNA-mediated silencing of FBXW11 or BTRC resulted in strong
YFP-RAPGEF2 (green), FLAG-BTRC, or FLAG-FBXW11 were fixed, stained for FLAG (red), and analyzed using epifluorescence microscopy. (G) HEK293 cells
were cotransfected with YFP-RAPGEF2 (green) and FLAG-BTRC or with YFP-RAPGEF2 (green) and FLAG-FBXW11, fixed, stained for FLAG (red), and
analyzed using epifluorescence microscopy. Note the large RAPGEF2 aggregate (arrowhead) and the localization of RAPGEF2 at the plasma membrane (arrow)
when coexpressed with FBXW11. (H) HEK293 cells cotransfected with YFP-RAPGEF2 (green) and FLAG-FBXW11 were fixed, stained for FLAG (red), and
analyzed by confocal microscopy. A single Z-slice is shown; orthogonal images are shown in vertical and horizontal boxes for the merged image. All imaging
studies were analyzed in two independent experiments imaged on two different days. DAPI was used to stain DNA. Scale bars, 20 m.
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FBXW11 & BTRC
FIG 3 RAPGEF2 is regulated by FBXW11/BTRC-mediated protein degradation. (A) Western blot analysis of HEK293 cells treated with 10 M MG132 for the
indicated periods of time. (B) Western blot analysis of HEK293 cells overexpressing FLAG-RAPGEF2 with or without overexpression of HA-FBXW11. (C)
Western blot analysis of HEK293 cells transfected with the indicated siRNAs. (D) HEK293 cells cotransfected with the indicated siRNAs and YFP-RAPGEF2 were
fixed 72 h posttransfection and analyzed by phase contrast and epifluorescence microscopy. Scale bar, 40 m. (E) HEK293 cells were transfected with control and
FBXW11/BTRC siRNAs and treated with 40 g/ml cycloheximide (CHX) for the indicated times. Cell lysates were subjected to immunoblot analysis with
anti-RAPGEF2, anti-BTRC, or anti--tubulin (TUBB) antibodies. (F) Control siRNAs or siRNAs cotargeting BTRC and FBXW11 were transfected into HEK293
and H2228 cells for 48 h. Cell lysates were subjected to immunoblot analysis with the indicated antibodies. ns, nonspecific. (G) Cell lysates from HEK293 cells
stably expressing shRNA against GFP or BTRC and FBXW11 were assessed by pulldown analysis with GST-RalGDS RAP-binding domain (RBD), and the
pulldown proteins were then immunoblotted with anti-RAP1 antibody to measure the levels of active GTP-RAP1.
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FIG 4 Identification of a degron motif within RAPGEF2 that is required for FBXW11 binding and ubiquitylation. (A) HEK293 cells were transfected with control
siRNAs or siRNAs cotargeting BTRC and FBXW11 for 24 h, followed by transfection with HA-ubiquitin (Ub) and FLAG-RAPGEF2 for 48 h. Cells were then
treated with MG132 for 6 h before immunoprecipitation and immunoblot analysis. (B) HEK293 cells were cotransfected with plasmids expressing FLAG-
RAPGEF2, HA-ubiquitin, and HA-BTRC or HA-FBXW11 for 48 h, followed by treatment with 10 M MG132 for 6 h. Immunoprecipitated FLAG-RAPGEF2
complexes were subjected to immunoblot analysis. (C) Amino acid sequence alignment of three degron motifs found within RAPGEF2. The sequence of an
alanine mutant motif 3 protein is shown at the bottom of the panel as 2SA. (D) RAPGEF2 degron motifs were individually deleted to yield the  constructs. These
were coexpressed with HA-FBXW11 in HEK293T cells before lysis, FLAG-IP, and immunoblot analysis for the indicated proteins. (E) HEK293 cells were
transfected with the indicated FLAG-tagged plasmids for 48 h followed by an 8-h CHX treatment. Cell lysates were subjected to immunoblot analysis with
anti-FLAG or anti--tubulin antibodies. (F) HEK293 cells were transfected with plasmids expressing the FLAG-tagged wild type or a 3 (deletion of the third
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suppression of RAPGEF2 ubiquitylation, and overexpression of
either BTRC or FBXW11 increased RAPGEF2 ubiquitylation
(Fig. 4A and B, respectively). The RAPGEF2 protein contains
three putative FBXW11/BTRC recognition domains, or degrons
(Fig. 4C). To determine which degron motif mediates FBXW11/
BTRC binding, three internal deletion mutants of RAPGEF2 were
constructed and evaluated by immunoprecipitation and Western
blot analysis. The RAPGEF2-3 mutant, in which the third potential
degron motif was deleted, failed to bind to HA-tagged FBXW11
(Fig. 4D). Compared to wild-type protein, the RAPGEF2-3 mu-
tant was considerably more stable after cycloheximide (CHX)
treatment and resulted in greater GTP loading of RAP1 (Fig. 4E to
G). To further validate and extend these data, we generated a
mutant in which two serine-to-alanine substitutions were intro-
duced (2SA) (Fig. 4C). RAPGEF2-2SA, like RAPGEF2-3, failed
to cocomplex with FBXW11 (Fig. 4H). RAPGEF2-2SA also dem-
onstrated reduced levels of ubiquitylation and concordantly in-
creased protein stability compared to wild-type RAPGEF2 (Fig. 4I
and J, respectively). Taken together, these results suggest that the
third degron motif in RAPGEF2 mediates FBXW11 binding and
ubiquitylation.
RAPGEF2 promotes multinucleation. While performing sub-
cellular localization studies of ectopically expressed RAPGEF2 in
HEK293 cells, we observed striking changes in nuclear morphol-
ogy (Fig. 5A, arrow). Specifically, RAPGEF2 overexpression re-
sulted in nuclear multilobulation (multiple lobes per nucleus) and
multinucleation (cells containing multiple distinct nuclei). In ad-
dition, a distinct subset of YFP-RAPGEF2-positive cells demon-
strated multinucleation, as evidenced by DAPI staining (Fig. 5A,
arrowheads). To quantitatively determine whether expression of
RAPGEF2 could induce the generation of multinucleated and
nuclear multilobulated cells, we transiently expressed YFP-
RAPGEF2 and quantified the percentage of YFP-RAPGEF2-posi-
tive cells containing 1, 2, 3, 4, or more nuclei, or a multilobulated
nucleus, at 24, 48, and 72 h posttransfection in lamin B immuno-
staining preparations. As seen in Fig. 5B, the percentage of multi-
nucleated cells at 24 h posttransfection was higher among cells
expressing YFP-RAPGEF2 (	13%) than among control GFP-
expressing cells (1.86%). Moreover, nuclear multilobulation was
found only in cells expressing YFP-RAPGEF2 (	2.90%). The per-
centages of both multinucleation and nuclear multilobulation
showed further increases at 48 h posttransfection in cells express-
ing YFP-RAPGEF2 (	22% and 12.5%, respectively) but did not
increase to the same extent in control cells (	3.5% and 0%, re-
spectively). At 72 h posttransfection, the percentages of multi-
nucleation and nuclear multilobulation were decreased in cells
expressing YFP-RAPGEF2 compared to cells expressing YFP-
RAPGEF2 at 48 h posttransfection. Despite these decreases, the
percentage of multinucleation at 72 h posttransfection was pro-
nouncedly higher in cells expressing YFP-RAPGEF2 than in con-
trol cells.
To further validate these phenotypes, we isolated a clonal pop-
ulation of HEK293 cells stably expressing YFP-RAPGEF2. In
agreement with the transient-transfection experiments, cells sta-
bly expressing YFP-RAGEF2 displayed increased multinucleation
compared to parental HEK293 cells (Fig. 5C and D). Interestingly,
the nuclear multilobulation observed in transient analyses was not
observed in either parental HEK293 cells or HEK293 cells stably
expressing YFP-RAPGEF2 (Fig. 5C and D).
Next, we tested whether RAPGEF2 overexpression resulted in
an increased DNA ploidy, as measured by DNA content analyses,
by flow cytometry. For this, HEK293 cells transiently transfected
with GFP or YFP-RAPGEF2 were stained with propidium iodide
48 h posttransfection. Overexpression of RAPGEF2 did not signif-
icantly affect cell cycle distributions. Consistent with the multi-
nucleation observed in our morphological analysis, RAPGEF2 ex-
pression increased the level of DNA content relative to control
transfected cell results (Fig. 5E). We also tested whether RAPGEF2
silencing impacted nuclear number or morphology. We found
that RAPGEF2 depletion by siRNA had no effect on the percent-
age of multinucleated cells and that no cells depleted of RAPGEF2
exhibited nuclear multilobulation (Fig. 5F and G). Moreover,
RAPGEF2 depletion had no effect on the cell cycle distribution or
the percentage of cells exhibiting DNA content greater than 4 N
(Fig. 5H). Altogether, these findings suggest that elevated expres-
sion of RAPGEF2 induces cell multinucleation.
RAPGEF2-induced multinucleation is independent of GEF
and RAP1 activities. To determine whether RAPGEF2-induced
multinucleation was dependent upon the RAPGEF catalytic activ-
ity, we generated a GEF-dead RAPGEF2 mutant. To accomplish
this, we modeled the primary sequence of the CDC25 homology
domain on the structure of the CDC25 homology domain of an-
other RAPGEF, EPAC2, bound to RAP1 (RCSB database identi-
fier 3CF6) (41). This model predicted residues within RAPGEF2
that mediate interaction with RAP1 (Fig. 6A and B). Mutant
RAPGEF2 harboring the triple mutation K875A/F879A/N884A
was constructed by site-directed mutagenesis, and its lack of GTP
exchange activity for RAP1 was confirmed by performing a RAP
pulldown assay (Fig. 6C). Unexpectedly, when overexpressed in
HEK293 cells, the GEF-dead RAPGEF2 mutant retained its ability
to promote both multinucleation and nuclear multilobulation
(Fig. 6D). Consistent with this, DNA content analysis demon-
strated an increase in the percentage of cells exhibiting DNA con-
tent greater than 4 N in populations expressing the dead-
RAPGEF2 mutant (Fig. 6E). To confirm these results, HEK293
cells were transfected with constitutively active or dominant-neg-
ative RAP1A and RAP1B (RAP1A/B) (RAP1-CA and RAP1-DN, re-
spectively) before quantitation of multinucleated cells; RAP1-CA and
RAP1-DN overexpression impacted neither the number nor the
shape of nuclei (Fig. 6D). These results support the idea of a GEF- and
RAP1-independent function for RAPGEF2 in controlling multi-
nucleation.
DSG motif) mutant of RAPGEF2 for 48 h followed by treatment with 40 g/ml CHX for the indicated time. Cell lysates were subjected to immunoblot analysis
with anti-FLAG or actin antibodies. (G) HEK293T cells were transfected with the indicated RAPGEF2 plasmid before lysis and assessment by pulldown analysis
with GST-RalGDS(RBD). The bound proteins were then were immunoblotted with anti-RAP1 antibody to measure the active GTP-RAP1 levels. (H) Two serine
residues in the third DSGXXS motif of RAPGEF2 were substituted with alanine to obtain the RAPGEF2 mutant (2SA). This mutant was transfected with
HA-FBXW11 into HEK293 cells, followed by treatment with 10 M MG132 for 2 h. Cell lysates or anti-HA immunoprecipitates were subjected to immunoblot
analysis with the indicated antibodies. (I) HEK293 cells were cotransfected with plasmids expressing HA-ubiquitin, FBXW11, and the FLAG-tagged wild type or
a 2SA mutant of RAPGEF2 for 48 h, followed by treatment with 10 M MG132 for 6 h. Equal amounts of anti-FLAG immunoprecipitates were subjected to
immunoblot analysis (IB) with anti-HA antibodies. (J) Western blot analysis of HEK293 cells expressing the FLAG-tagged wild type or a 2SA mutant of RAPGEF2
after 40 g/ml CHX treatment for the indicated times.
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Multinucleation can result from several distinct processes, includ-
ing cytokinesis failure, cell-cell fusion, centrosome overduplication,
and endoreplication (42, 43). To further delineate the cellular mech-
anism(s) by which RAPGEF2 promotes multinucleation, we per-
formed time-lapse microscopy of HEK293 cells transiently
expressing YFP-RAPGEF2 alone or in combination with cherry-
NLS. Both experiments revealed that RAPGEF2 overexpression
promoted cell-cell fusion events, and, perhaps surprisingly, alter-
ations in cytokinesis were not observed (Fig. 6F; see also Videos S1
and S2 in the supplemental material). These data suggest that
RAPGEF2 promotes the generation of multinucleated cells by in-
ducing cell-cell fusion.
DISCUSSION
In general, the phenotypic importance of an E3 ubiquitin ligase
complex can be inferred from the function of its substrates and the
nature of ubiquitin chain linkage. Until recently, comprehensive
substrate identification has been challenging. Several experimen-
tal approaches now provide generally applicable and unbiased
technologies for medium-throughput substrate identification.
These approaches, including their relative strengths and weak-
nesses, have been recently reviewed by Harper and Tan (8). The
parallel adaptor capture proteomics (PAC) method uses compar-
ative mass spectrometry analysis of immunopurified ubiquitin li-
gase adapter proteins to identify putative substrates. Proteins
which increase in abundance within the purified E3 complex after
proteasome or NEDD8 inhibition constitute candidate substrates
and substrate-associated proteins. The PAC-based method was
used to study 23 unique E3 adapter proteins, including 21 leucine-
rich repeat FBXL proteins (13). Of 27 putative new substrates
identified, 13 demonstrated increased protein levels following
NEDD8 inhibition, supporting the idea of ubiquitin-dependent
turnover. Here, we used PAC-based proteomics to study the
FBXW11 ubiquitin ligase adapter protein. We discovered 96 in-
teracting proteins, 23 of which demonstrated increased associa-
tion after proteasome inhibition. These new putative substrates
FIG 5 RAPGEF2 induces multinucleation in a GEF- and Rap1-activity-independent fashion. (A) HEK293 cells transiently expressing YFP-RAPGEF2 were fixed
and imaged using epifluorescence microscopy. DAPI was used for DNA labeling. Note the presence of nuclear multilobulated (arrow) and multinucleated
(arrowhead) cells. (B) Quantification of multinucleation and nuclear multilobulation. HEK293 cells transfected with HcRed (control) or RAPGEF2 were scored
based on number of nuclei and nuclear lobulation at 24 h and 48 h posttransfection. n, number of cells scored. (C) Parental HEK293 cells and cells stably
expressing YFP-RAPGEF2 were fixed, stained for lamin B (cyan) and tubulin (red), and imaged using epifluorescence microscopy. Note the presence of
multinucleated cells (arrowheads). (D) Quantification of multinucleation and nuclear multilobulation in parental HEK293 cells and cells stably expressing
YFP-RAPGEF2. (E) Cell cycle distribution analyses by flow cytometry of parental HEK293 cells and HEK293 cells transfected with GFP or WT-RAPGEF2 stained
with propidium iodide. Data are shown as means 
 standard errors of the means (SEM) of the results of triplicate biological experiments. (F) HEK293 cells
transfected with the indicated siRNAs and stained for lamin B (cyan) and tubulin (red). (G) Quantification of multinucleation and nuclear multilobulation in the
cells whose results are shown in panel F. Data are representative of the results of three independent replicate biological experiments. (H) Cell cycle distribution
analyses by flow cytometry of mock-transfected HEK293 cells or HEK293 cells transfected with RAPGEF2 siRNAs and stained with propidium iodide. Data are
shown as means 
 SEM of the results of triplicate biological experiments. Scale bars, 20 m.
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include TBC1D4, SUN2, STK3, and the recently reported
RAPGEF2 protein (28).
Taken together, our results further support the power of PAC-
based proteomics for E3 substrate identification. That said, PAC
data sets must be interpreted wisely. First, an appreciation of the
high false-discovery rates common to IPMS studies is needed;
probabilistic scoring algorithms for IPMS data sets are conve-
niently provided by SAINT, HGScore, and CompPASS (39, 44,
45). Second, PAC-based interaction networks and identified can-
didate substrates are not comprehensive. Monoubiquitylated sub-
strates and those not degraded by the proteasome are unlikely to
experience enrichment within PAC-based analyses. For example,
we did not identify the lysosomal targeted SCFFBXW11 substrates
IFNAR1 and PRLR within our studies (46, 47). Last, the relative
abundances and kinetics of substrate turnover must be consid-
ered; a low-abundance substrate with a low rate of ubiquitylation
and/or degradation does not experience enrichment to the same
degree as rapidly catalyzed substrates. Time course studies would
prove informative. By extension, whereas most substrates exhibit

























































GFP 5.64 (± 0.67)
WT RAPGEF2 16.09 (± 0.73)
Dead RAPGEF2 14.38 (± 0.95)
F
FIG 6 RAPGEF2-induced multinucleation is GEF and Rap1 activity independent. (A) Homology model of RAPGEF2·RAP1. (Left) The Cdc25 domain of
RAPGEF2 was modeled using the protein homology/analogy recognition engine 2 (Phyre2) server (71) and superimposed on the structure of EPAC2·RAP1 (41)
using Coot (72). The Cdc25 domain of RAPGEF2 is shown as a yellow ribbon, while Mg2/nucleotide-free RAP1 is depicted in green with nucleotide-dependent
switches (sw1 and sw2) colored red. Residues Lys 875, Phe 879, and Asn 884 (cyan) within the “helical hairpin” (H and I) (73, 74) of the Cdc25 domain of
RAPGEF2 are essential for interactions with bound RAP1 and GEF-catalyzed exchange. (B) An expanded view of the boxed area (left) highlights the multiple
polar and hydrophobic interactions between residues in the helical hairpin and RAP1. Dashed lines indicate hydrogen bonding. (C) RAP1 pulldown assay with
HEK293 cells that were mock transfected or transfected with the wild type or the dead-RAPGEF2 mutant by using GST-RalGDS-RBD beads. (D) Quantification
of multinucleation and multilobulation in HEK293 cells transiently expressing HcRed (control), RAPGEF2-WT, RAPGEF2-GEF-dead, constitutively active
RAP1 (RAP1 CA), or dominant-negative RAP1 (RAP1 DN). Data are representative of the results of two independent replicate biological experiments. (E)
Percentages of cells exhibiting DNA content greater than 4 N. HEK293 cells were transfected with GFP or wild-type or GEF-dead RAPGEF2, stained with
propidium iodide, and analyzed by flow cytometry. Data are shown as mean percentages 
 SEM of the results of triplicate biological experiments. (F) Time-lapse
images of HEK293 cells cotransfected with cherry-nuclear localization signal (Cherry-NLS) and YFP-RAPGEF2. Cells were imaged for 19 h at 6-min intervals.
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strates, for example, HNRNPU, may show no change or a decrease
within the complex (48).
Several of the putative substrates we identified have not previ-
ously been associated with ubiquitylation, regulated protein sta-
bility, or the SCFFBXW11 complex. TBC1D4 encodes a GAP for the
small GTPase Rab that controls insulin-dependent trafficking of
the GLUT4 glucose transporter in skeletal muscle cells and in adi-
pocytes (49, 50). Upon insulin stimulation, AKT induces phos-
phorylation of TBC1D4 at multiple sites, inactivating its GAP ac-
tivity, which in turn prevents translocation of GLUT4 from
intracellular storage vesicles to the cell surface (51, 52). The im-
portance of TBC1D4 in human disease was recently illustrated
though genetic association studies of a Greenlandic population
experiencing a rapidly increasing incidence of type 2 diabetes (53).
That study revealed a homozygous truncating variant in TBC1D4
in 17% of the population; allele carriers, even in the heterozygous
state, demonstrated impaired glucose homeostasis. Our data sug-
gest a new mechanism by which TBC1D4 activity might be regu-
lated and an additional link between FBXW11 and glucose ho-
meostasis. It was also recently reported that SCFFBXW11 negatively
regulates the stability of ELAV1 and PFKFB3, both of which reg-
ulate glycolysis and energy homeostasis (54, 55).
SUN2, together with SUN1, localizes at the inner nuclear
membrane (56, 57), and both proteins interact with lamin pro-
teins at the inner nuclear membrane and recruit KASH proteins to
the outer nuclear membrane, playing an important role in proper
positioning of the nucleus in cells (58) and in the DNA damage
response (59), as well as contributing to the progression of lamin-
opathies (60). Of note, it was recently suggested that SUN proteins
are accumulated in cells that express lamin A mutations, leading
to cellular toxicity mediated by Golgi disruption and hyperactive
DNA damage response (61). Therefore, it is possible that the in-
creased stability of SUN proteins in lamin A-defective cells is at-
tributable to SCFFBXW11-mediated protein stability regulation.
We focused our biochemical and functional studies on RAPGEF2,
a guanine exchange factor (GEF) for the RAP1/2 small GTPases.
While we were preparing this paper for publication, Magliozzi et
al. reported the ubiquitylation of RAPGEF2 by SCFFBXW11 and
SCFBTRC (28). RAPGEF2 ubiquitylation and subsequent degrada-
tion required priming phosphorylation by IB kinase beta (IKK)
and CK1 and was triggered by promigratory signals. Expression
of degron mutant RAPGEF2 led to increased RAP1 activity and
suppression of cell migration. Our findings, including the identi-
fication of the degron motif and the activation of RAP1 activity
following FBXW11 silencing, strongly agree with those reported
by Magliozzi et al. However, in contrast to their findings, we found
that preventing FBXW11-mediated RAPGEF2 degradation
caused RAP1- and GEF-independent promotion of cell fusion and
multinucleation.
Consistent with their physical interaction, we found that ex-
pression of RAPGEF2 affected the subcellular localization of
BTRC and FBXW11 and, reciprocally, that expression of BTRC
and FBXW11 affected RAPGEF2 localization. RAPGEF2 localizes
to sites of cell-cell contact, partially colocalizing with CTNNB1
and TJP1 (62). RAPGEF2 also physically interacts with the MAGI
proteins, which in turn bind CTNNB1 at cell-cell contacts to re-
cruit RAP1 (63). Our observation that RAPGEF2 is mainly dif-
fusely cytosolic when expressed alone under subconfluent condi-
tions but colocalizes with FBXW11 at the plasma membrane sites
may support the idea of a role for RAPGEF2 as a scaffold protein.
Specifically, RAPGEF2 may carry or recruit FBXW11 to the cell
cortex, where it impacts the ubiquitylation of a distinct pool
of binding partners. In this context, we hypothesize that the
RAPGEF2-FBXW11 complex and possibly associated proteins re-
spond to cell confluence and contribute to downstream signaling
pathways. We also detected RAPGEF2 at centrosomes; this was
confirmed by colocalization studies performed with gamma-tu-
bulin (data not shown). These results suggest that RAPGEF2 may
play different roles, some of which may not require GEF activity,
in different subcellular compartments.
The most striking phenotype we observed when interrogating
the FBXW11-RAPGEF2 interaction was the appearance of cells
with multiple nuclei following RAPGEF2 overexpression. While
further study is needed to establish the precise cellular mechanism
of multinucleation, our live-cell microscopy experiments revealed
that RAPGEF2 overexpression results in cell-cell fusions and sur-
prisingly, does not impact mitosis or cell cycle progression. Given
its role and location within membrane-associated protein com-
plexes, it is possible that RAPGEF2 induces changes in cell-cell
adhesion properties that result in altered cell permeability and
membrane fusion. An important unresolved issue regards the epi-
static and phenotypic relationships between BTRC/FBXW11 loss,
RAPGEF2 increase, and multinucleation/aneuploidy. In other
words, does FBXW11/BTRC loss result in RAPGEF2-dependent
multinucleation, and is this mediated by cell-cell fusion? Many
studies have shown that FBXW11 and BTRC deficiency results in
cell cycle arrest, centrosome duplication, and mitotic spindle dys-
function, owing to failed degradation of various substrates, in-
cluding EMI1(FBXO5), REST, CDC25A, WEE1, PLK1, and PLK4
(64). Spermatids from BTRC knockout mice display multinucle-
ation (65). Although the experiments are incomplete, our data
suggest that loss of function for FBXW11 and BTRC results in
rapid cell cycle arrest, centrosome amplification, and multinucle-
ation in a manner independent of cell-cell fusion. It is likely that
the altered cell cycle progression masks any effect of FBXW11/
BTRC on RAPGEF2-dependent cell-cell fusion. Acute and spa-
tially restricted FBXW11/BTRC inhibition would be required to
test this model.
RAPGEF2 is a well-known and physiologically important acti-
vator of RAP1 (26, 28, 63, 66). Our data unexpectedly reveal GEF-
and RAP-independent functions of RAPGEF2. Specifically, both
wild-type RAPGEF2 and GEF-dead RAPGEF2 induced multi-
nucleation and, further, neither dominant-negative nor constitu-
tively active mutants of RAP1 affected multinucleation. To our
knowledge, this is the first example of a GEF-independent func-
tion for RAPGEF2. Further structure-function analysis of other
RAPGEF2 protein domains would provide valuable insight into
the underlying mechanics of multinucleation. Additionally, epi-
statically positioning RAPGEF2-associated proteins such as
MAGI1, MAGI3, and PTPN13 with respect to multinucleation
and cell fusion is needed.
Cellular multinucleation that arises through cell-cell fusion is a
required event for normal development and tissue homeostasis
(67). For instance, macrophages undergo fusion leading to the
generation of osteoclasts and giant cells, which play fundamental
roles in bone absorption and in chronic inflammation, respec-
tively. Likewise, skeletal muscle development occurs through fu-
sion of mononucleated myoblasts (68), while placenta develop-
ment requires the formation of the trophoblastic syncytium (69).
Cell fusion is a genetically programmed process that can be di-
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vided into three stages: competence (cell induction and differen-
tiation), commitment (cell determination, migration, and adhe-
sion), and cell fusion (membrane merging and cytoplasmic
mixing) (70). Despite its importance and morphological charac-
terization, relatively little is known about the regulatory pathways
that control cell-cell fusion. Our current report provides evidence
that RAPGEF2 functions in a GEF-independent fashion to medi-
ate cell-cell fusion events.
Based on our data, RAPGEF2 overexpression and multinucle-
ation might be predicted to contribute to the cancer phenotype.
Specifically, multinucleated cells likely exhibit increased suscepti-
bility to mitotic/cytokinesis abnormalities which could promote
genomic instability. Consistent with this, RAPGEF2 and its inter-
acting protein MAGI-2 were independently identified in an in vivo
low-copy-number piggyBac insertional mutagenesis screen for
drivers of melanoma (27). In that study, transposon mutagenesis
(transpogenesis) within the RAPGEF2 locus was predicted to re-
sult in an overexpressed full-length protein. In comparison,
RAPGEF2 overexpression and subsequent RAP1 activation sup-
pressed invasion and dissemination in breast cancer models (28).
Although the idea is speculative, it is possible that RAPGEF2 pro-
motes tumorigenesis early via RAP1-independent cell fusions and
represses cancer progression late through RAP1-dependent inhi-
bition of metastasis. Alternatively, RAPGEF2 may differentially
impact tumor cell biology depending on the cell type.
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